Revvity Omics Inc.

Revvity Omics Inc., operating under the doing business as name Perkinelmer Genetics, is a for-profit subsidiary of Revvity Inc. that specializes in genetic testing and newborn screening services for federal agencies, particularly the U.S. military healthcare system. The company is registered in SAM.gov as a corporate entity and has maintained active federal contracting status since its registration in June 2002. Revvity Omics Inc. provides comprehensive laboratory diagnostic capabilities focused on early detection of genetic and metabolic conditions in newborns through specialized screening and testing services delivered to military treatment facilities located globally.

The company's federal contract portfolio demonstrates consistent specialization in newborn screening and genetic testing services provided exclusively to military healthcare agencies without the use of small business set-asides. Revvity Omics Inc. has secured multiple purchase orders and delivery orders from the Defense Health Agency and the Department of the Army Medical Command for newborn screening testing services at military medical facilities worldwide, including locations in South Korea, Germany, Italy, and various U.S. military bases such as Fort Bliss, Texas; Fort Irwin, California; and Aviano Air Base, Italy. The services provided encompass comprehensive newborn screening panels that test for conditions including galactosemia, hypothyroidism, cystic fibrosis, glucose-6-phosphate dehydrogenase deficiency, and hemoglobinopathies, with performance standards requiring 72-hour turnaround for initial results and confirmatory testing within 5-10 business days. The company maintains required CAP/CLIA accreditation and FDA licensing to perform these testing services. Recent contract awards include a $848,688 purchase order from the Defense Health Agency awarded October 1, 2024, for newborn genetic testing services at William Beaumont Army Medical Center extending through September 30, 2029, and a $197,264 purchase order for newborn genetic screening services awarded August 10, 2023, with completion scheduled for August 9, 2028. Additional awards include contracts valued at $165,711.65 for Weed Army Community Hospital, $371,000 for comprehensive newborn screening services, and various smaller delivery orders for Brian D. Allgood Army Community Hospital in South Korea ranging from approximately $8,900 to $44,700.

Revvity Omics Inc. holds two active indefinite delivery contract vehicles as a single-award prime contractor. The primary vehicle is a $301,668 Indefinite Delivery Contract awarded by the Defense Health Agency on September 29, 2024, for newborn screening testing services at Brian D. Allgood Army Community Hospital in South Korea, with a base period extending from September 29, 2024, through September 28, 2025, and four one-year option periods extending through September 28, 2029. Task orders have been issued under this indefinite delivery contract, including delivery orders valued at $40,945.50 awarded September 29, 2024; $44,716.56 awarded September 29, 2023; and subsequent orders totaling approximately $4,549.50 and $42,993, demonstrating active utilization of this vehicle through firm fixed-price delivery order placement mechanisms. The company also holds a $150,000 Blanket Purchase Agreement awarded by the Department of the Air Force United States Air Forces in Europe - Air Forces Africa on September 10, 2023, for newborn metabolic screening test services at Spangdahlem Air Base in Germany, with order placement authority extending through September 9, 2028. Together, these contract vehicles provide Revvity Omics Inc. with approximately $451,668 in potential contract value across military healthcare operations in both overseas and domestic locations, positioning the company as an established provider of specialized diagnostic services to the defense medical establishment.